^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

m-ceNK cells

i
Other names: m-ceNK cells, memory cytokine-enriched natural killer cells
Associations
Company:
ImmunityBio
Drug class:
NK cell stimulant, IFNγ stimulant
Related drugs:
Associations
28d
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Metastases
|
CD4 (CD4 Molecule) • NKG2D (killer cell lectin like receptor K1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
over1year
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, ImmunityBio, Inc. | N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
over3years
Clinical • Enrollment open
|
CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
over3years
Clinical • New P1 trial
|
CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells